"In the context of drug discovery, the hope for precision medicine has long been on the horizon"
Despite dramatic advances in annotation of the genetic architecture for common chronic diseases, there has not been the same progress in refined treatments.
Are the common diseases behind simply because of the inherent time lag between target discovery and translation? Or will their inherent multifactorial nature and heterogeneity prove more resistant to refined treatment paradigms?
Get Lon's presentation in seconds.
Fill in the form opposite.